<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492908</url>
  </required_header>
  <id_info>
    <org_study_id>KEK237_06</org_study_id>
    <nct_id>NCT00492908</nct_id>
  </id_info>
  <brief_title>Randomized Trial Comparing Titan Stent With Zotarolimus-Eluting Stent</brief_title>
  <official_title>Randomized Clinical Trial Comparing A Titanium-Nitride-Oxide Coated Stent With A Zotarolimus-Eluting Stent in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Comparison of a Titanium-Nitride-Oxide Coated Stent (Helistent Titan2, Hexacath)
      With a Zotarolimus-Eluting Stent (EndeavorTm, Medtronic) for Percutaneous Coronary
      Intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The purpose of this study is to compare the Titanium-Nitride-Oxide Coated Stent
      (Helistent Titan2, Hexacath) with a Zotarolimus-Eluting Stent (EndeavorTm, Medtronic) in a
      non-inferiority trial.

      Design: Prospective, multi-center, randomized, non-inferiority trial to be conducted at 3
      Swiss interventional cardiology centers. Patients will be randomized in a single-blind
      fashion (1:1 randomization) to either the Titanium-Nitride-Oxide Coated Stent (Helistent
      Titan2, Hexacath) or the Zotarolimus-Eluting Stent (EndeavorTm, Medtronic).

      Study Population: Patients with symptomatic coronary artery disease including patients with
      chronic stable angina, silent ischemia, unstable angina, and non-ST elevation myocardial
      infarction, who qualify for percutaneous coronary interventions

      Antiplatelet Therapy: Aspirin 100 mg qd indefinitely; Clopidogrel 75 mg qd for 3 months

      Enrollment: A total of 300 patients will be enrolled

      All patients will undergo repeat angiography at 6-8 months.

      All patients will be followed for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late luminal loss</measure>
    <time_frame>6-8 months after stent implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLR, TVR, Death or MI, CV death or MI, CV death, Death, MI, Stent thrombosis, Stenosis, Restenosis</measure>
    <time_frame>30 days, 6-8 months, 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Titanium Nitride Oxide Coated Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zotarohlimus Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helistent Titan2 (Titanium coated stent)</intervention_name>
    <description>Titan2</description>
    <arm_group_label>Titanium Nitride Oxide Coated Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndeavorTM (Zotarolimus-Eluting Stent)</intervention_name>
    <description>Endeavor</description>
    <arm_group_label>Zotarohlimus Eluting Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The following patients are eligible for inclusion

          1. Age ≥18 years

          2. Symptomatic coronary artery disease including patients with chronic stable angina,
             silent ischemia, unstable angina, and non-ST elevation myocardial infarction

          3. Presence of one or more coronary artery stenoses &gt;50% in a native coronary artery from
             2.25 to 4.0 mm in diameter that can be covered with one or multiple stents;

          4. No limitation on the number of treated lesions, and vessels, and lesion length

        Exclusion Criteria:

          1. Pregnancy

          2. Known intolerance to aspirin, clopidogrel, heparin, stainless steel, titan,
             zotarolimus or contrast material

          3. Inability to provide informed consent

          4. Currently participating in another trial before reaching first endpoint

          5. ST segment elevation myocardial infarction (STEMI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Windecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, University Hospital Bern, Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T, Wenaweser P, Togni M, Tüller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation. 2005 May 24;111(20):2617-22. Epub 2005 May 9.</citation>
    <PMID>15883209</PMID>
  </reference>
  <reference>
    <citation>Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G, Leskosek B, Meier B, Hess OM; Working Group on Novel Surface Coating of Biomedical Devices (SCOL). Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation. 2001 Aug 21;104(8):928-33.</citation>
    <PMID>11514381</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <name_title>Department of Cardiology</name_title>
    <organization>Bern University Hospital</organization>
  </responsible_party>
  <keyword>Coronary Revascularization</keyword>
  <keyword>Titanium-Nitride-Oxide Coated Stent</keyword>
  <keyword>Zotarolimus-Eluting Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

